Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04463004 · ClinicalTrials.gov registry record · Phase 2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04463004 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 2 participants.
The verdict
NCT04463004, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammation.
Interventions
- DRUG Placebos
- DRUG Mavrilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2020-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04463004
The ClinicalTrials.gov registry entry for NCT04463004 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04463004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04463004 about?
NCT04463004 is a clinical study titled "Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation". The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammati...
What is the current status of trial NCT04463004?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-09-02. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT04463004?
The interventions under investigation include: Placebos (DRUG), Mavrilimumab (DRUG).
Who is sponsoring clinical trial NCT04463004?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.